Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 740

1.

Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.

Comaschi M, Demicheli A, Di Pietro C, Bellatreccia A, Mariz S; COM06 Study Investigators.

Diabetes Technol Ther. 2007 Aug;9(4):387-98.

PMID:
17705695
[PubMed - indexed for MEDLINE]
2.

The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.

Comaschi M, Corsi A, Di Pietro C, Bellatreccia A, Mariz S; COM06 Study Investigators.

Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):373-9. Epub 2007 Oct 24.

PMID:
17919894
[PubMed - indexed for MEDLINE]
3.

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

Diabetes Care. 2004 Jan;27(1):141-7.

PMID:
14693980
[PubMed - indexed for MEDLINE]
4.

Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.

Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):6-13. Epub 2007 Dec 20.

PMID:
18095238
[PubMed - indexed for MEDLINE]
5.

Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.

Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT.

Drugs Aging. 2004;21(4):259-71.

PMID:
15012171
[PubMed - indexed for MEDLINE]
6.

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.

Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M.

Diabetologia. 2005 Jun;48(6):1093-104. Epub 2005 May 12.

PMID:
15889234
[PubMed - indexed for MEDLINE]
7.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
[PubMed - indexed for MEDLINE]
8.

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23. doi: 10.1111/j.1365-2710.2008.00984.x.

PMID:
19125899
[PubMed - indexed for MEDLINE]
10.

Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.

Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, Chow CC, Shaban J.

Clin Ther. 2005 Sep;27(9):1432-43.

PMID:
16291416
[PubMed - indexed for MEDLINE]
11.

2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.

Seufert J, Urquhart R.

Diabetes Res Clin Pract. 2008 Mar;79(3):453-60. Epub 2007 Dec 26.

PMID:
18160120
[PubMed - indexed for MEDLINE]
12.

Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.

Diabetes Obes Metab. 2006 Nov;8(6):650-60.

PMID:
17026489
[PubMed - indexed for MEDLINE]
13.

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

PMID:
16505505
[PubMed - indexed for MEDLINE]
15.

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

Clin Ther. 2004 May;26(5):744-54.

PMID:
15220018
[PubMed - indexed for MEDLINE]
16.

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.

PMID:
20015525
[PubMed - indexed for MEDLINE]
17.

Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.

Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C.

J Assoc Physicians India. 2003 Nov;51:1061-4.

PMID:
15260389
[PubMed - indexed for MEDLINE]
18.

The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.

Rajagopalan R, Xu Y, Abbadessa M; Quartet Study Group.

Am J Geriatr Pharmacother. 2006 Jun;4(2):123-33.

PMID:
16860259
[PubMed - indexed for MEDLINE]
19.
20.

Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen.

Rendell MS, Glazer NB, Ye Z.

J Diabetes Complications. 2003 Jul-Aug;17(4):211-7.

PMID:
12810245
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk